# Accelerated long-term forgetting as a predictor of clinical onset in presymptomatic autosomal dominant Alzheimer's disease.

- **DOI:** [10.1136/jnnp-2025-336750](https://doi.org/10.1136/jnnp-2025-336750)
- **Rating:** Sound (3.2 out of 5)
- **Verdict:** Longitudinal ALF testing identifies a promising presymptomatic ADAD prognostic signal, but internally inconsistent headline statistics prevent confident interpretation.
- **Framework version:** v5.9
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-10-08
- **Evaluation page:** https://www.nabu.science/paper/10.1136%2Fjnnp-2025-336750

## Key claims

1. Severity of ALF is not only associated with the presence of AD pathology but also predictive of clinical onset, identifying those at the highest risk of imminent decline.
   - Support: Tentative
   - Type: Primary finding
   - Basis: small observational cohort without validated time-to-event prediction, compounded by inconsistent headline statistics
   - Location: Abstract, Conclusions
2. Those who became symptomatic had lower baseline ALF scores for both the list
   - Support: Supported
   - Type: Secondary
   - Basis: reported medians support the direction within this small cohort, although inferential uncertainty remains
   - Location: Results, paragraph 1; Abstract
3. Story ALF (area under curve (AUC)=0.82) and list ALF (AUC=0.73) discriminated between those who did and did not develop symptoms.
   - Support: Tentative
   - Type: Secondary
   - Basis: in-sample AUCs from nine events lack uncertainty and conflict with the reported rank-test p-values
   - Location: Abstract; Results, Figure 1C
4. No differences were found between those who did become symptomatic and those who did not become symptomatic for any of the other more conventional cognitive assessments.
   - Support: Tentative
   - Type: Secondary
   - Basis: the same 20-person cohort is underpowered to establish that conventional measures lack prognostic association
   - Location: Results, paragraph 3; Table 1

## Strengths

- **Extended follow-up in genetically defined carriers** The cohort comprised asymptomatic ADAD mutation carriers with annual clinical assessment over a median of seven years, allowing baseline ALF to be related prospectively to later CDR-defined progression.
  - Dimension: contribution
  - Location: Methods, Participants and Procedures; Results, paragraph 1
- **Relevant within-cohort cognitive comparators included** Three ALF modalities and eight conventional tests spanning memory, executive function, and global intellectual function were analysed in the same cohort. The negative figure result was reported alongside the verbal findings.
  - Dimension: methodological rigour
  - Location: Methods, Statistical Analysis; Results, paragraphs 1 and 3
- **Clear connection to presymptomatic trial needs** The Discussion identifies trial recruitment, cognitive endpoints, and treatment stratification as concrete potential uses while also noting implementation burden and the need for replication.
  - Dimension: application pathway
  - Location: Discussion, paragraphs 3–4 and 6

## Limitations

- **Headline statistics are internally inconsistent** For the same two-group ALF predictors, the reported rank-test p-values imply substantially stronger separation than the AUCs in Figure 1C. This discrepancy affects the numerical basis of the central discrimination claim and requires resolution.
  - Dimension: methodological rigour
  - Location: Results, paragraph 1; Figure 1C; Discussion, paragraph 1
- **Discrimination estimates lack validation and uncertainty** AUCs are estimated and evaluated in the same 20-person cohort, with no confidence intervals, calibration assessment, cross-validation, or external validation. Nine progression events therefore support all predictive interpretation.
  - Dimension: methodological rigour
  - Location: Methods, Statistical Analysis; Results, Figure 1C
- **Clinical language exceeds the studied evidence** Claims about identifying imminent decline and wider-population screening go beyond an ADAD-only cohort with no validated time-to-event prediction or demonstrated transfer to sporadic disease.
  - Dimension: reporting
  - Location: Abstract, Conclusions; Discussion, final paragraph

## Reliability checks

Caveats (4 of 4 checks).

- **Results check:** Noted
  - Story ALF (area under curve (AUC)=0.82) and list ALF (AUC=0.73) discriminated between those who did and did not develop symptoms: "story (progressors=58.8 (IQR, 44–66), non-progressors=81.2 (IQR, 69.1–87.8), p<0.001)" (Results, first paragraph) vs "story ALF (area under curve (AUC)=0.82)" (Results, first paragraph). Using 9 progressors and 11 non-progressors, treating the rounded AUC as the rank-order probability and ignoring ties gives z=(0.82−0.5)√(12×9×11/21)≈2.407 and a two-sided normal-approximation p≈0.016, rather than an exact reconstruction of the stated Kruskal–Wallis test. → Conclusion holds
- **Reporting and transparency:** Clean. No supplied concern establishes a reporting or research-conduct finding.
  - Conflict of interest: not stated · Ethics approval: declared · Preregistration: not stated · Data availability: not stated · Code availability: not stated
- **Reference integrity:** Clean. 18 of 18 checkable references verified
  - 18 references in manuscript
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17
